0001213900-23-092661.txt : 20231204 0001213900-23-092661.hdr.sgml : 20231204 20231204160111 ACCESSION NUMBER: 0001213900-23-092661 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20231128 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231204 DATE AS OF CHANGE: 20231204 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Elevai Labs Inc. CENTRAL INDEX KEY: 0001840563 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 851399981 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41875 FILM NUMBER: 231462927 BUSINESS ADDRESS: STREET 1: 120 NEWPORT CENTER DRIVE STREET 2: STE 250 CITY: NEWPORT BEACH STATE: CA ZIP: 92660 BUSINESS PHONE: 18667944940 MAIL ADDRESS: STREET 1: 120 NEWPORT CENTER DRIVE STREET 2: STE 250 CITY: NEWPORT BEACH STATE: CA ZIP: 92660 FORMER COMPANY: FORMER CONFORMED NAME: Reactive Medical Labs Inc. DATE OF NAME CHANGE: 20210114 8-K 1 ea189451-8k_elevailabs.htm CURRENT REPORT

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): November 28, 2023

Elevai Labs, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-41875

85-1399981

(State or other jurisdiction

of incorporation)

(Commission File Number)

(I.R.S. Employer

Identification No.)

c/o 120 Newport Center Drive, Ste. 250

Newport Beach, CA

92660

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: 866-794-4940

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value		ELAB		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item. 1.01 Entry into a Material Definitive Agreement.

On November 28, 2023, Elevai Labs, Inc., a Delaware corporation (the “Company”), entered into a collaboration and license agreement (the “Collaboration Agreement”) with Yuva BioSciences, Inc., a Delaware corporation (“Yuva”). Under the Collaboration Agreement, Yuva and the Company have agreed to collaborate on the research, development, manufacture and commercialization of a potentially new cosmetic product for Company’s aesthetics skincare offerings.

The Company will conduct joint trials within the initial six months of the Collaboration Agreement in order to assess Yuva’s licensed compound for the purpose of evaluating that licensed compound’s effect on improving the appearance of skin.

Under the Collaboration Agreement, the Company has non-exclusive, nontransferable, non-assignable, royalty-bearing rights and a license, with the right to sublicense certain of Yuva’s intellectual property to develop, manufacture and commercialize cosmetic products that contains Yuva’s proprietary compound and any of the Company’s exosome-based ingredients, or products under which exosomes serve as a carrier for Yuva’s proprietary compound in the United States, Canada and other mutually agreed to territories (the “Licensed Cosmetic Product”).

In consideration for the rights granted to the Company under the Collaboration Agreement, the Company has assumed all costs associated with the development, manufacture and commercialization incurred under the agreement and paid Yuva $5,000 as an upfront cash payment. The Company has further agreed to royalty payment obligations (i) for a minimum royalty during the five (5) years following the anniversary of the completion of any joint trials, and (ii) for earned royalties through net sales on a product basis during the latter of either (x) eight (8) years following November 28, 2023 or (y) the expiration of the last to expire valid claim of the licensed patents covering Yuva’s intellectual property used in such Licensed Cosmetic Product in any of the previously agreed to territories, or (z) ten (10) years after the first commercialization date of any Licensed Cosmetic Product on a country-by-country basis ((i)-(ii), collectively the “Royalty Obligations”).

The Collaboration Agreement will remain in effect, unless earlier terminated on a country-by-country basis, until (a) at the one year anniversary of the joint trial completion date, in Yuva’s reasonable determination, the Company has not (i) taken measurable actions to commercialize the Licensed Cosmetic Product, (ii) developed draft marketing materials for sale of Licensed Cosmetic Product, or (iii) paid in full its obligations for minimum royalties; (b) as of the second anniversary of the joint trial completion date, no net sales have accrued; (c) in Yuva’s reasonable judgement, the Company has failed to exert commercially reasonable efforts to development, manufacture or commercialization a Licensed Cosmetic Product. As an alternative to Yuva’s termination right, Yuva may offer the continuation of the Collaboration Agreement subject to an amendment to revise the Company’s Royalty Obligations.

The Collaboration Agreement also contains customary provisions for termination by either party, including in the event of breach of the Collaboration Agreement, subject to cure. Upon termination, all licenses granted by the Yuva to the Company will terminate.

The Collaboration Agreement includes customary representations and warranties on behalf of both the Company and Yuva. The Collaboration Agreement also provides for customary mutual indemnities. In addition, the Collaboration Agreement imposes certain exclusivity obligations on Yuva and the Company, respectively, with respect to the development, use, manufacture and commercialization of the Licensed Cosmetic Product. Neither party may assign the Collaboration Agreement or delegate its obligations to an affiliate or to a successor to certain of the business to which the Collaboration Agreement relates without the consent of the other party.

The foregoing is only a summary of certain provisions of the Collaboration Agreement and is qualified in its entirety by the terms of the Collaboration Agreement, a copy of which will be filed as an exhibit to the Company’s quarterly report on Form 10-Q for the quarter ended September 30, 2023. Pursuant to Item 601(b)(10)(iv) of Regulation S-K, the Company intends to redact from the filed copy of the Collaboration Agreement certain information that is both (i) not material and (ii) is the type of information that the Company treats as private or confidential.

Item 7.01 Regulation FD Disclosure.

On November 29, 2023, the Company issued a press release announcing that it had entered into the Collaboration Agreement and the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information furnished pursuant to Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that section, nor shall it be deemed to be incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly set forth by specific reference in such filing.

1

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

The following exhibits are being filed herewith:

Exhibit No.		Description
99.1*		Press Release of the Company dated as of November 29, 2023
104		Cover Page Interactive Data File (embedded with the Inline XBRL document).

*	Furnished herewith.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: December 4, 2023

Elevai Labs, Inc.

By:	/s/ Jordan R. Plews
Name:	Jordan R. Plews
Title:	Chief Executive Officer, President and Director

3

EX-99.1 2 ea189451ex99-1_elevailabs.htm PRESS RELEASE OF THE COMPANY DATED AS OF NOVEMBER 29, 2023

Exhibit 99.1

Elevai Labs Enters into Licensing Agreement with Yuva Biosciences to Combine Exosome and Mitochondrial Technologies to Develop New Aesthetics Products

NEWPORT BEACH, Calif., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (Nasdaq: ELAB) a medical aesthetic company specializing in physician-dispensed skincare, today announced that they have signed a licensing agreement with Yuva Biosciences, Inc. to research and develop means to incorporate Yuva Bioscience’s mitochondrial research with ELEVAI’s PREx™ (Precision Regenerative Exosome Technology™) to potentially develop topical skincare formulations that combine mitochondrial biology with Elevai’s human umbilical mesenchymal stem cell derived exosomes.

Elevai currently markets its proprietary ELEVAI E-Series which are peri-procedure topical exosome skincare products. Yuva Biosciences utilizes mitochondrial science to address signs of aging of hair, scalp, and skin. Yuva Biosciences has built a platform that includes a leading-edge AI model to rapidly screen huge numbers of natural compounds for their effectiveness in improving mitochondrial health.

“We are excited to partner with Yuva Biosciences in order to begin research and development of products that may incorporate the power of mitochondrial technology to further advance the potential of Elevai exosomes to address cosmetic skin and hair concerns associated with signs of aging,” said Jordan R. Plews PhD and CEO of ELEVAI Labs.

“YuvaBio, in partnership with Elevai, is researching topical cosmetic applications that may limit the appearance of human aging and we believe this research and development partnership has the potential to commercialize new cosmetics not found elsewhere,” commented Keshav K. Singh, PhD, Scientific Founder of Yuva Biosciences.

About ELEVAI Labs

ELEVAI Labs Inc. is a medical aesthetics company developing cutting-edge physician-dispensed skin care applications. The company solves unmet needs in the medical aesthetics space through a combination of cutting-edge science-driven and next-generation consumer applications. ELEVAI Labs develops topical aesthetic skin care cosmetic products for the physician-dispensed market, with a focus on leveraging a proprietary stem cell exosome technology. For more information visit www.elevaiskincare.com.

About Yuva Biosciences

Yuva Biosciences is an anti-aging company harnessing the cutting edge of mitochondrial science to develop cosmeceuticals as well as pharmaceuticals targeted at aging-related hair loss, wrinkled skin, and multiple other aging-related conditions. The Company’s Scientific Founder and Chief Scientific Advisor, Keshav K. Singh, Ph.D., is a world leader in the field of mitochondrial biology and genetics and its role in health, disease, and aging. Dr. Singh is the Joy and Bill Harbert Endowed Chair and Professor of Genetics, Pathology and Dermatology at the University of Alabama at Birmingham, and the founding editor-in-chief of the Mitochondrion journal published by Elsevier. Yuva Biosciences is headquartered in Birmingham, Alabama. For more information visit www.yuvabio.com.

Forward-Looking Statements

Certain statements made in this press release are "forward-looking statements'' within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "anticipate", "believe", "expect", "estimate", "plan", "outlook", and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements reflect the current analysis of existing information and are subject to various risks and uncertainties. As a result, caution must be exercised in relying on forward looking statements. Due to known and unknown risks, actual results may differ materially from the Company’s expectations or projections. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: (i) the failure to meet projected research & development and production targets; (ii) changes in applicable laws or regulations; and (iii) other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the Securities and Exchange Commission (the "SEC"). These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions and the completion of the initial public offering on the anticipated terms or at all, and other factors discussed in the “Risk Factors” section of the registration statement filed with the SEC. The Company’s SEC filings are available publicly on the SEC’s website at www.sec.gov. Any forward-looking statement made by us in this press release is based only on information currently available to the Company and speaks only as of the date on which it is made. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law.

Media Contact
Brenda Buechler
Chief Marketing Officer
contact@elevailabs.com

Investor Relations
IR@elevailabs.com

EX-101.LAB 3 elab-20231128_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 4 elab-20231128_pre.xml XBRL PRESENTATION FILE EX-101.SCH 5 elab-20231128.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink XML 6 R1.htm IDEA: XBRL DOCUMENT

Cover	Nov. 28, 2023
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Nov. 28, 2023
Entity File Number	001-41875
Entity Registrant Name	Elevai Labs, Inc.
Entity Central Index Key	0001840563
Entity Tax Identification Number	85-1399981
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	c/o 120 Newport Center Drive
Entity Address, Address Line Two	Ste. 250
Entity Address, City or Town	Newport Beach
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92660
City Area Code	866
Local Phone Number	794-4940
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, $0.0001 par value
Trading Symbol	ELAB
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false

XML 7 ea189451-8k_elevailabs_htm.xml IDEA: XBRL DOCUMENT 0001840563 2023-11-28 2023-11-28 iso4217:USD shares iso4217:USD shares 0001840563 false 8-K 2023-11-28 Elevai Labs, Inc. DE 001-41875 85-1399981 c/o 120 Newport Center Drive Ste. 250 Newport Beach CA 92660 866 794-4940 false false false false Common Stock, $0.0001 par value ELAB NASDAQ true false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://elevailabsinc.com/role/Cover Cover Cover 1 false false All Reports Book All Reports ea189451-8k_elevailabs.htm elab-20231128.xsd elab-20231128_lab.xml elab-20231128_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ea189451-8k_elevailabs.htm": { "nsprefix": "ELAB", "nsuri": "http://elevailabsinc.com/20231128", "dts": { "inline": { "local": [ "ea189451-8k_elevailabs.htm" ] }, "schema": { "local": [ "elab-20231128.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "elab-20231128_lab.xml" ] }, "presentationLink": { "local": [ "elab-20231128_pre.xml" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://elevailabsinc.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2023-11-28", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "ea189451-8k_elevailabs.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-11-28", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "ea189451-8k_elevailabs.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://elevailabsinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://elevailabsinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://elevailabsinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://elevailabsinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://elevailabsinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://elevailabsinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://elevailabsinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://elevailabsinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://elevailabsinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://elevailabsinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://elevailabsinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://elevailabsinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://elevailabsinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://elevailabsinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://elevailabsinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://elevailabsinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://elevailabsinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://elevailabsinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://elevailabsinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://elevailabsinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://elevailabsinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://elevailabsinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://elevailabsinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://elevailabsinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://elevailabsinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://elevailabsinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://elevailabsinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://elevailabsinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://elevailabsinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://elevailabsinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://elevailabsinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://elevailabsinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://elevailabsinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://elevailabsinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://elevailabsinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://elevailabsinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://elevailabsinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://elevailabsinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://elevailabsinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://elevailabsinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://elevailabsinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://elevailabsinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://elevailabsinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://elevailabsinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://elevailabsinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://elevailabsinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://elevailabsinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://elevailabsinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://elevailabsinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://elevailabsinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://elevailabsinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://elevailabsinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://elevailabsinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://elevailabsinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://elevailabsinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://elevailabsinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://elevailabsinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://elevailabsinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 14 0001213900-23-092661-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-23-092661-xbrl.zip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end